scholarly journals Stool and urine trefoil factor 3 levels: associations with symptoms, intestinal permeability, and microbial diversity in irritable bowel syndrome

2018 ◽  
Vol 9 (3) ◽  
pp. 345-355 ◽  
Author(s):  
M.M. Heitkemper ◽  
K.C. Cain ◽  
R.J. Shulman ◽  
R.L. Burr ◽  
C. Ko ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Microbial Diversity ◽  
Intestinal Permeability ◽  
Trefoil Factor ◽  
Contraception Use ◽  
Trefoil Factor 3 ◽  
Rome Iii ◽  
Irritable Bowel ◽  
Stool Microbiota ◽  
Relationship Of

Previously we showed that urine trefoil factor 3 (TFF3) levels were higher in females with irritable bowel syndrome (IBS) compared to non-IBS females. To assess if TFF3 is associated with symptoms and/or reflect alterations in gastrointestinal permeability and gut microbiota in an IBS population, we correlated stool and urine TFF3 levels with IBS symptoms, intestinal permeability, stool microbial diversity and relative abundance of predominant bacterial families and genera. We also tested the relationship of stool TFF3 to urine TFF3, and compared results based on hormone contraception use. Samples were obtained from 93 females meeting Rome III IBS criteria and completing 4-week symptom diaries. TFF3 levels were measured by ELISA. Permeability was assessed with the urine lactulose/mannitol (L/M) ratio. Stool microbiota was assessed using 16S rRNA. Stool TFF3, but not urine TFF3, was associated positively with diarrhoea and loose stool consistency. Higher stool TFF3 was also associated with lower L/M ratio and microbial diversity. Of the 20 most abundant bacterial families Mogibacteriaceae and Christensenellaceae were inversely related to stool TFF3, with only Christensenellaceae remaining significant after multiple comparison adjustment. There were no significant relationships between stool or urine TFF3 levels and other symptoms, nor between stool and urine levels. In premenopausal females, urine TFF3 levels were higher in those reporting hormone contraception. Collectively these results suggest that higher stool TFF3 levels are associated with IBS symptoms (loose/diarrhoeal stools), lower gut permeability, and altered stool bacteria composition (decreased diversity and decreased Christensenellaceae), which further suggests that TFF3 may be an important marker of host-bacteria interaction.

scholarly journals The Relationship Between Irritable Bowel Syndrome , Depression , Anxiety, and Stress among a Sample of Irritable Bowel Patients - Predictive Study

2016 ◽  
Vol 7 (1) ◽  
Author(s):  
Osama Hasan Gaber
Keyword(s):  
Irritable Bowel Syndrome ◽  
Pearson Correlation ◽  
Depression Symptoms ◽  
Rome Iii ◽  
Prediction Coefficient ◽  
Irritable Bowel ◽  
Relationship Of ◽  
Anxiety Depression ◽  
The Relationship ◽  
Predictive Study

<p>This study aimed to examine the relationship of irritable bowel syndrome, anxiety, depression and stress among a sample of78 IBS patients (Rome III Diagnostic Criteria for Irritable Bowel Syndrome),anxiety symptoms scale ,Depression symptoms scale ,and stress scale (prepared by the researcher) were used Pearson Correlation Coefficient showed that there are statistically significant relationship between IBS and Anxiety ,Depression and Stress (P≤=0.01).The Regression and Prediction Coefficient (stepwise) was also used and showed that the depression and Stress of predicts to IBS.<strong></strong></p>

scholarly journals Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-κB and notch signalling pathways

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Qiuke Hou ◽  
Yongquan Huang ◽  
Zhaoyang Zhu ◽  
Liu Liao ◽  
Xinlin Chen ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Intestinal Permeability ◽  
Rat Model ◽  
Distal Colon ◽  
Notch Signalling ◽  
Signalling Pathways ◽  
Model Group ◽  
Related Factors ◽  
Defecation Frequency ◽  
Irritable Bowel

Abstract Background Tong-Xie-Yao-Fang (TXYF) has been shown to be effective in diarrhoea-predominant irritable bowel syndrome (IBS-D) patients. However, the underlying mechanism remains to be clarified. The aim of this study was to investigate the efficacy and related mechanisms of TXYF in an IBS-D rat model. Methods The IBS-D rat model was established with 4% acetic acid and evaluated by haematoxylin-eosin (HE) staining. Then, IBS-D rats were divided into control, TXYF and rifaximin groups and treated intragastrically with normal saline, TXYF and rifaximin, respectively, for 14 days. The following indicators were measured before and after treatment: defecation frequency, faecal water content (FWC) and colorectal distension (CRD). Histopathological changes in the distal colon were observed after treatment. The expression of OCLN and ZO1 in the distal colon of IBS-D rats reflected the intestinal mucosal permeability, as measured by qRT-PCR, western blot, and enzyme-linked immunosorbent assays (ELISAs). The NF-κB and Notch signalling pathways and inflammation-related factors were investigated. Results After treatment with TXYF, the defecation frequency, FWC and CRD were significantly lower than those in the model group (P < 0.05). HE staining showed that colonic epithelial cells (CECs) in the IBS-D rats displayed significant oedema, impaired intestinal mucosal integrity and an increased influx of inflammatory cells. A significant reduction in granulocyte and CEC oedema was observed after the administration of TXYF and rifaximin compared to that of the model group and blank group (P < 0.05). TXYF significantly upregulated the expression of OCLN and ZO-1 and downregulated inflammation-related factors (IL-6, IL-1β, and TNF-α and the chemokine KC) in IBS-D rats compared to those in the model group rats (P < 0.05). In terms of the NF-κB and Notch signalling pathways, the expression of NICD, p-ERK, Hes-1 and p-P65 decreased significantly in the TXYF and rifaximin groups, while the expression of ATOH1 increased significantly compared to that in the model group (P < 0.05). Conclusion TXYF can effectively improve intestinal permeability and enhance intestinal mucosal barrier function, which may be related to inhibition of the inflammatory cascade and the NF-κB and Notch signalling pathways.

scholarly journals Serotonin-Related Gene Variants in Patients with Irritable Bowel Syndrome and Depressive or Anxiety Disorders

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Magdalena Grzesiak ◽  
Jan Aleksander Beszłej ◽  
Ewa Waszczuk ◽  
Marcin Szechiński ◽  
Monika Szewczuk-Bogusławska ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Anxiety Disorders ◽  
Depressive Disorders ◽  
Composite International Diagnostic Interview ◽  
Diagnostic Interview ◽  
Nucleotide Polymorphisms ◽  
Single Nucleotide ◽  
New Findings ◽  
Rome Iii ◽  
Irritable Bowel

Aim. To assess the association of six polymorphisms in serotonin-related genes with depressive or anxiety disorders in patients with irritable bowel syndrome (IBS).Methods. The lifetime prevalence of depressive and anxiety disorders was assessed in 95 IBS patients (85% women) using the Munich version of the Composite International Diagnostic Interview (CIDI). IBS was diagnosed according to the Rome III criteria.SCL6A4HTTLPR polymorphism (rs4795541) was determined using PCR-based method. Single-nucleotide polymorphisms inHTR1A(rs6295),HTR2A(rs6313 and rs6311),HTR2C(rs6318), andTPH1(rs1800532) were detected by minisequencing method.Results. IBS patients with depressive disorders were characterized by higher frequency of 5-HTTLPR L allele in comparison to IBS patients with anxiety disorders. The lower frequency of 1438 A allele inHTR2Awas found in IBS patients with depressive disorders in comparison to IBS patients without mental disorders. The lower G allele frequency inHTR2Crs6318 polymorphism among IBS patients with anxiety disorders was also observed.Conclusions. Our results provide further evidence for the involvement ofSLC6A4rs4795541 andHTR2Ars6311 polymorphisms in the pathophysiology of depressive disorders in IBS patients. The new findings indicate thatHTR2Crs6318 polymorphism may be associated with the susceptibility to anxiety disorders in IBS patients.

Sign in / Sign up

Export Citation Format

Share Document